Platinum-induced hearing loss after treatment for childhood cancer

As, Jorrit W van; Berg, Henk van den; Dalen, Elvira C. van

doi:10.1002/14651858.cd010181

Cited by 4 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given inconsistent and low‐certainty evidence, no definitive conclusions can be drawn about the impacts of treatment‐induced HL. However, the findings reiterate previous accounts based on the general paediatric population 5,10,14,15 that some CCS may experience competing hearing, communication, academic and social challenges. This emphasises the importance of multidisciplinary care for CCS at risk of treatment‐induced HL who are already vulnerable to other physical, cognitive and psychological late effects of cancer treatment 28,31 .…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Communication, academic and social outcomes of childhood cancer survivors with hearing loss: A systematic review

Carter

Boisvert

Docking

2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Many children treated for cancer are at risk of hearing loss. However, little is known about how hearing loss impacts their communication, academic and social outcomes. To examine the impact, this systematic review aimed to synthesise and appraise quantitative and qualitative studies reporting on (i) participants with hearing loss treated with platinum‐based chemotherapy or cranial radiotherapy during childhood; and (ii) speech, language, academic performance, or social participation findings. Systematic database searches yielded 23 relevant articles that were analysed using narrative synthesis. Difficulties were reported for some but not all communication, academic and social aspects; however, a quality assessment using Grading of Recommendations Assessment, Development and Evaluation (GRADE) revealed low to very low certainty in the findings. Future research should aim to increase the quality of the research evidence and explore how multidisciplinary services can provide evidence‐based support for childhood cancer survivors with competing hearing, communication, and social difficulties.

show abstract

Section: Discussionsupporting

confidence: 83%

“…This type of HL is typically bilateral, resulting from irreversible and often progressive damage to structures within the inner ear 7–9 . While the prevalence of treatment‐induced HL is unclear, a 2016 Cochrane Review found that studies reported between 1.7% and 90.1% of CCS have some degree of HL after platinum chemotherapy 10 …”

Section: Introductionmentioning

confidence: 99%

Communication, academic and social outcomes of childhood cancer survivors with hearing loss: A systematic review

Carter

Boisvert

Docking

2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…As a result, there is a wide variation in reported HL risk. 1 Mean RT dose to the cochlea is associated with HL in pediatric patients 2,5,11,12 and although no randomized comparison with photon RT exists, proton therapy may decrease ototoxicity risk by keeping the cochlea dose low. [13][14][15] In addition, platinum-based chemotherapy agents, such as cisplatin and carboplatin, contribute to ototoxicity, the effect of which is similarly dosedependent.…”

Section: Introductionmentioning

confidence: 99%

“…Ototoxicity is an irreversible late effect of the radiotherapy (RT), cisplatin or carboplatin exposure 1 necessary for the curative treatment of many CNS and head-and-neck (H&N) tumors in children. 2 These exposures may result in high-frequency hearing loss (HL), which can progress to additional loss at lower frequencies, with a latency period of several years post-treatment.…”

Section: Introductionmentioning

confidence: 99%

Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children

Keilty

Khandwala

Liu

et al. 2021

JCO

View full text Add to dashboard Cite

PURPOSE Hearing loss (HL) is a serious secondary effect of treatment for CNS and head-and-neck tumors in children. The goal of this study was to evaluate incidence and risk factors for HL in patients with multiple ototoxic exposures. PATIENTS AND METHODS We evaluated 340 ears from 171 patients with CNS or head-and-neck tumors treated with radiation, with or without chemotherapy, who had longitudinal audiologic evaluation. International Society of Pediatric Oncology-Boston grades were assigned to 2,420 hearing assessments. Multivariable weighted ordinal logistic regression was fitted to evaluate the effect of clinicopathologic features on HL. RESULTS Mean cochlea dose (odds ratio [OR] 1.04 per Gy, P < .001), time since radiotherapy (RT; OR 1.21 per year, P < .001), cisplatin dose (OR 1.48 per 100 mg/m2, P < .001), and carboplatin dose (OR 1.41 per 1,000 mg/m2, P = .002) were associated with increasing International Society of Pediatric Oncology-Boston grade of HL. There was no synergistic effect of RT and cisplatin (interaction term, P = .53) or RT and carboplatin (interaction term, P = .85). Cumulative incidence of high-frequency HL (> 4 kHz) was 50% or greater at 5 years after RT if mean cochlea dose was > 30 Gy, while incidence of HL across all frequencies continued to increase beyond 5 years after RT. CONCLUSION Children treated with radiation and chemotherapy experience a high incidence of HL over time, with associations found between more severe HL and cisplatin or carboplatin dose as well as mean cochlea dose. Mean cochlea dose of ≤ 30 Gy is proposed as a goal to reduce the risk of HL; a lower threshold (20-25 Gy) may be considered in patients receiving platinum chemotherapy to reduce cumulative HL burden.

show abstract

“…Platinum compounds have been widely utilized to treat different malignancies 1–3 . Although they are highly effective at controlling malignant tumors, they have several undesirable side effects including ototoxicity 4 . At present, there are no clinically approved or effective approaches to prevent ototoxicity caused by platinum‐based chemotherapy 1,5 .…”

Section: Introductionmentioning

confidence: 99%

Glutathione carbon dots as an intracellular reactive oxygen species scavenger for reducing cisplatin‐induced ototoxicity

Tu,

Fan,

et al. 2023

VIEW

View full text Add to dashboard Cite

It is widely recognized that platinum‐based chemotherapy, particularly cisplatin therapy, can cause ototoxicity. At present, there are no Food and Drug Administration‐approved drugs to prevent or alleviate ototoxicity. Ototoxicity is generally believed to be caused by excessive reactive oxygen species production in the inner ear. Accordingly, a variety of antioxidants have been developed to protect against ototoxicity. To improve the efficiency of drug delivery to the cochlea, here, we synthesized simple and easy‐to‐obtain glutathione carbon dots (GSH CDs) with ultra‐small dimensions. The experimental results revealed that the GSH CDs have strong free‐radical scavenging activity and can restore mitochondrial function, maintain hair cell stability, and protect hair cells from cisplatin‐induced oxidative stress. Thus, GSH CDs may serve as a new therapeutic agent for preventing cisplatin‐induced ototoxicity.

show abstract

Platinum-induced hearing loss after treatment for childhood cancer

Cited by 4 publications

References 16 publications

Communication, academic and social outcomes of childhood cancer survivors with hearing loss: A systematic review

Communication, academic and social outcomes of childhood cancer survivors with hearing loss: A systematic review

Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children

Glutathione carbon dots as an intracellular reactive oxygen species scavenger for reducing cisplatin‐induced ototoxicity

Contact Info

Product

Resources

About